NTLA
Overvalued by 121.6% based on the discounted cash flow analysis.
Market cap | $2.06 Billion |
---|---|
Enterprise Value | $1.14 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-5.42 |
Beta | 1.86 |
Outstanding Shares | 96,438,608 |
Avg 30 Day Volume | 1,200,832 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -4.27 |
---|---|
PEG | -25.84 |
Price to Sales | - |
Price to Book Ratio | 2.18 |
Enterprise Value to Revenue | 31.53 |
Enterprise Value to EBIT | -2.15 |
Enterprise Value to Net Income | -3 |
Total Debt to Enterprise | 0 |
Debt to Equity | 0 |
No data
No data
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...